Behavior of Smooth Muscle Cells under Hypoxic Conditions: Possible Implications on the Varicose Vein Endothelium. 2018

Miguel A Ortega, and Beatriz Romero, and Ángel Asúnsolo, and Felipe Sainz, and Clara Martinez-Vivero, and Melchor Álvarez-Mon, and Julia Buján, and Natalio García-Honduvilla
Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, Alcalá de Henares, Madrid, Spain.

Varicose veins are a disease with high incidence and prevalence. In the venous wall, the smooth muscle cells (SMCs) act in the vascular homeostasis that secretes multiple substances in response to stimuli. Any alteration of these cells can modify the function and structure of the other venous layers such as the endothelium, resulting in increases in endothelial permeability and release of substances. Therefore, knowing the cellular and molecular mechanisms of varicose veins is imperative. The aims of this study are to understand how SMCs of patients with varicose veins subjected to saphenectomy of the great saphenous vein react under hypoxic cell conditions and to determine the role of vascular endothelial growth factor (VEGF) in this process. We obtained SMCs from human saphenous vein segments from patients with varicose veins (n=10) and from organ donors (n=6) undergoing surgery. Once expanded, the cells were subjected to hypoxic conditions in specific chambers, and expansion was examined through analyzing morphology and the expression of α-actin. Further gene expression studies of HIF-1α, EGLN3, VEGF, TGF-β1, eNOS, and Tie-2 were performed using RT-qPCR. This study reveals the reaction of venous cells to sustained hypoxia. As significant differential gene expression was observed, we were able to determine how venous cells are sensitive to hypoxia. We hypothesize that venous insufficiency leads to cellular hypoxia with homeostatic imbalance. VEGF plays a differential role that can be related to the cellular quiescence markers in varicose veins, which are possible therapeutic targets. Our results show how SMCs are sensitive to hypoxia with a different gene expression. Therefore, we can assume that the condition of venous insufficiency leads to a situation of sustained cellular hypoxia. This situation may explain the cellular response that occurs in the venous wall as a compensatory mechanism.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004730 Endothelium, Vascular Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components. Capillary Endothelium,Vascular Endothelium,Capillary Endotheliums,Endothelium, Capillary,Endotheliums, Capillary,Endotheliums, Vascular,Vascular Endotheliums
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D014648 Varicose Veins Enlarged and tortuous VEINS. Varices,Varix,Varicose Vein,Vein, Varicose,Veins, Varicose
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D015687 Cell Hypoxia A condition of decreased oxygen content at the cellular level. Anoxia, Cellular,Cell Anoxia,Hypoxia, Cellular,Anoxia, Cell,Anoxias, Cell,Anoxias, Cellular,Cell Anoxias,Cell Hypoxias,Cellular Anoxia,Cellular Anoxias,Cellular Hypoxia,Cellular Hypoxias,Hypoxia, Cell,Hypoxias, Cell,Hypoxias, Cellular
D042461 Vascular Endothelial Growth Factor A The original member of the family of endothelial cell growth factors referred to as VASCULAR ENDOTHELIAL GROWTH FACTORS. Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as "tumor angiogenesis factor" and "vascular permeability factor". Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating VASODILATION via NITRIC OXIDE-dependent pathways. Alternative splicing of the mRNA for vascular endothelial growth factor A results in several isoforms of the protein being produced. Vascular Endothelial Growth Factor,Vascular Endothelial Growth Factor-A,GD-VEGF,Glioma-Derived Vascular Endothelial Cell Growth Factor,VEGF,VEGF-A,Vascular Permeability Factor,Vasculotropin,Glioma Derived Vascular Endothelial Cell Growth Factor,Permeability Factor, Vascular

Related Publications

Miguel A Ortega, and Beatriz Romero, and Ángel Asúnsolo, and Felipe Sainz, and Clara Martinez-Vivero, and Melchor Álvarez-Mon, and Julia Buján, and Natalio García-Honduvilla
July 2001, Zentralblatt fur Chirurgie,
Miguel A Ortega, and Beatriz Romero, and Ángel Asúnsolo, and Felipe Sainz, and Clara Martinez-Vivero, and Melchor Álvarez-Mon, and Julia Buján, and Natalio García-Honduvilla
August 1999, Archives des maladies du coeur et des vaisseaux,
Miguel A Ortega, and Beatriz Romero, and Ángel Asúnsolo, and Felipe Sainz, and Clara Martinez-Vivero, and Melchor Álvarez-Mon, and Julia Buján, and Natalio García-Honduvilla
January 2004, Biological chemistry,
Miguel A Ortega, and Beatriz Romero, and Ángel Asúnsolo, and Felipe Sainz, and Clara Martinez-Vivero, and Melchor Álvarez-Mon, and Julia Buján, and Natalio García-Honduvilla
November 2013, International journal of molecular medicine,
Miguel A Ortega, and Beatriz Romero, and Ángel Asúnsolo, and Felipe Sainz, and Clara Martinez-Vivero, and Melchor Álvarez-Mon, and Julia Buján, and Natalio García-Honduvilla
August 1996, The Journal of surgical research,
Miguel A Ortega, and Beatriz Romero, and Ángel Asúnsolo, and Felipe Sainz, and Clara Martinez-Vivero, and Melchor Álvarez-Mon, and Julia Buján, and Natalio García-Honduvilla
April 1973, Virchows Archiv. A, Pathology. Pathologische Anatomie,
Miguel A Ortega, and Beatriz Romero, and Ángel Asúnsolo, and Felipe Sainz, and Clara Martinez-Vivero, and Melchor Álvarez-Mon, and Julia Buján, and Natalio García-Honduvilla
January 2011, Experimental and clinical cardiology,
Miguel A Ortega, and Beatriz Romero, and Ángel Asúnsolo, and Felipe Sainz, and Clara Martinez-Vivero, and Melchor Álvarez-Mon, and Julia Buján, and Natalio García-Honduvilla
January 1985, Acta anatomica,
Miguel A Ortega, and Beatriz Romero, and Ángel Asúnsolo, and Felipe Sainz, and Clara Martinez-Vivero, and Melchor Álvarez-Mon, and Julia Buján, and Natalio García-Honduvilla
January 2006, Circulation research,
Miguel A Ortega, and Beatriz Romero, and Ángel Asúnsolo, and Felipe Sainz, and Clara Martinez-Vivero, and Melchor Álvarez-Mon, and Julia Buján, and Natalio García-Honduvilla
April 2022, Biomedicines,
Copied contents to your clipboard!